Sponsored Content by MGI Reviewed by Olivia Frost, October 24, 2024
Groundbreaking advances in genomics have transformed the systematic examination of cellular systems throughout human history, improving our understanding of our world and enabling researchers and medical professionals to be more precise and objective than ever before. Diagnosis and treatment are now possible.
Image credit: Piyaset/Shutterstock.com
Researchers have utilized and integrated diverse omics data in this pursuit. Combining each ‘omics’ in confluence provides a more unbiased, comprehensive, and representative insight into the complex molecular mechanisms that underpin biological processes.
MGI’s innovative approach to sequencing combines three powerful technologies: electronic sensors, fluorescence, and self-illumination.
These advances benefit from the flexibility of integrating short-read (DNBSEQ™) and long-read (CyloneSEQ) sequencing, allowing MGI to offer an industry-leading SEQ ALL portfolio.
The SEQ ALL platform provides a wide range of end-to-end solutions for diverse applications including spatial omics, high-throughput genomics, and single-cell omics.
MGI is currently the only global provider to offer such an expansive, integrated workflow, allowing researchers to benefit from an unparalleled combination of scale, versatility, and precision.
The SEQ ALL portfolio accelerates pioneering discoveries across a variety of omics fields, revolutionizing scientists’ approaches to exploring and understanding complex biological systems.
Image credit: MGI
DNA-omics promises more comprehensive insights into complex diseases
There has been much debate about the unique characteristics of long-read and short-read genome sequencing.
Short read sequencing is suitable for detailed examination of specific DNA segments. Long-read approaches allow researchers to obtain a more comprehensive picture of the molecular information under study.
Combining both approaches can address individual constraints and enable a more complete DNA analysis.
MGI’s efficient workflow ensures accurate results through a comprehensive portfolio of clinical ultra-high, high, and medium-throughput sequencers backed by the company’s proprietary DNBSEQ technology.
The PCR-free DNBSEQ platform boasts many advantages, including high accuracy, low index misalignment, and low duplication rate.
MGI’s ability to perform large-scale sequencing while maintaining efficiency, stability, data quality, and affordability is widely recognized throughout the industry.
Earlier this year, the company introduced the Standard MPS 2.0 (SM 2.0) upgrade of its DNBSEQ platform, complementing its superior sequencing quality and increasing the percentage of Q40 bases.
MGI has also added CycloneSEQ long-lead technology to its product range. The company can now sequence long strands of DNA/RNA molecules without having to split them into smaller pieces.
Long-read technology offers significant advantages in genomics, transcriptomics, epigenomics, and other fields because it can generate ultra-long read lengths, perform real-time analysis, and perform rapid reads.
CycloneSEQ has already demonstrated potential in a variety of applications, including de novo assembly of whole human genomes, metagenomics sequencing, variant calling, and single-cell RNA sequencing.
It can also accurately and comprehensively detect complex genetic conditions such as thalassemia. This has been successfully applied to generate intertelomere genomic profiles in small animals.
Employing both MGI’s short-read and long-read sequencing technologies provides users with improved results and more comprehensive genetic testing in a variety of research and applied settings.
The company’s long-read sequencing technology can generate reads ranging from 10 kb to 1 Mb, compensating for the length limitations of short-read technology, where accuracy is its strength.
Access to more sequencing options also increases efficiency and cost-effectiveness for customers seeking a one-stop-shop solution for diverse research requirements.
Multi-omics enables deeper understanding of biological processes
Beyond DNA sequencing capabilities, MGI boasts DNA, cellular, and specialty omics (DCS) options, making it ideal for cutting-edge science based on DNBSEQ technology.
MGI’s cell omics products include a complete package suitable for single-cell library preparation and sequencing via a single platform, the DNBelab C Series high-throughput single-cell 5′ RNA and V(D)J library preparation; Kit included.
When used with the DNBelab C-TaiM 4 droplet generator, this kit enables efficient droplet encapsulation of cells in just 12 minutes. When used with DNBC4Tools analysis software, 20,000 cells per slide per run enables preparation of single-cell 5′ RNA, TCR, and BCR libraries for robust data quality control analysis It will be.
MGI introduced its revolutionary FluoXpert technology in April 2024. This technology transforms genome sequencers by incorporating multiplexed immunofluorescence capabilities, integrating image-based proteomics detection and sequencing capabilities within a single instrument.
FluoXpert allows researchers to detect more than 20 proteins in a single tissue section, providing valuable insight into applications such as precision medicine and high-throughput spatial sequence validation.
Many users of MGI’s sequencing equipment in spatial omics have successfully applied stereo-seq technology to conduct detailed studies in a number of areas.
Stereo-seq, based on DNA Nanoball technology, is the only spatial technology that can access the entire transcriptome with true single-cell resolution. Capture intracellular data through Ultra-HD resolution while providing field of view options greater than 160 cm2.
Researchers will also benefit from powerful tools that allow them to study spatial biology over a wide field of view at subcellular resolution. Whether working with fresh frozen tissue or formalin-fixed paraffin-embedded tissue, transcriptome analysis can be performed simultaneously at the tissue, cellular, and subcellular levels.
Capturing mRNA on a chip and using spatial barcoding allows for in situ sequencing, linking gene expression to cell morphology and microenvironment.
The chip is comprised of billions of DNA NanoBalls and is compatible with MGI’s DNBSEQ sequencing platform, which supports stereo-seq systems.
MGI will launch the DCS Lab Initiative in 2023 to provide end-to-end products for clinical and research applications in DNA genomics, cell-omics, and spatial-omics. The company has now successfully established 10 international laboratories focused on cutting-edge science.
Image credit: MGI
SEQ ALL integrates high-throughput DNB sequencing, cell omics, nanopore sequencing, and spatiotemporal genomics, giving users worldwide access to an end-to-end solution spanning multi-omics approaches, read length, and throughput. .
These capabilities will make omics more comprehensive, accurate, and affordable, improving access to genomic testing, and enabling the public to receive rapid and accurate diagnosis and treatment.
The company’s extensive international network and stable logistics system support MGI’s efforts to improve efficiency throughout the experimental process while fostering innovation across the life sciences industry.
As a global industry leader in tool development, MGI aims to advance DNA-omics, cellular-omics, and spatiotemporal-omics in SEQ ALL, enabling pioneering solutions that further enhance the life sciences.
Acknowledgment
Prepared based on material originally produced by BGI Health (HK) Co., Ltd.
About MGI
MGI Tech Co., Ltd. (MGI) is committed to building core tools and technologies to lead the life sciences through intelligent innovation. MGI focuses on the research, development, manufacturing, and sales of DNA sequencing instruments, reagents, and related products to support life sciences research, agriculture, precision medicine, and healthcare. MGI is a leading manufacturer of clinical high-throughput gene sequencers, and its multi-omics platforms include gene sequencing, mass spectrometry, medical imaging, and test automation.
Founded in 2016, MGI has more than 2,900 employees, nearly half of whom are in research and development. MGI operates in more than 100 countries and territories and has established multiple research and production locations around the world. Delivering real-time, comprehensive, lifelong solutions, the company’s vision is to provide effective and affordable healthcare solutions for everyone.
Sponsored Content Policy: News-Medical.net will only accept existing commercial relationships with us if the content adds value to News-Medical.Net’s core editorial philosophy of educating and informing the site. Publish articles and related content that may be derived from certain sources. Visitors interested in medical research, science, medical devices, and treatments.
